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Dear editor
We appreciate the editorial comments and suggestions by McFarland included here, as well as the ability to respond to their critique. This author makes several valid points about the type of data, which is clearly needed to better understand the impact of specific probiotics on Clostridium difficle-associated diarrhea (CDAD) prevention. The previously published meta-analysis entitled "Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis" was performed to evaluate the impact of probiotics on CDAD. 1 Given existing data, the only means to answer this question via meta-analysis required that all existing data be pooled. That said, we also conducted a subgroup analysis based on the genus of probiotic, to determine which probiotic genus (Lactobacillus, Bifidobacterium, and Saccharomyces) were most beneficial at preventing CDAD. The category "mixture of probiotics" included strains from more than one probiotic genus. As suggested by McFarland in their editorial, additional more detailed subgroup analysis based on unique probiotic species would be ideal; however, given the variation in specific species utilized in published reports, the paucity of published randomized control trials (RCTs) evaluating each species, and the fact that the vast majority of all published RCTs included a combination of different probiotic species, a subgroup analysis by probiotic species was not possible.
As mentioned in the "Discussion" section, there are limitations to our published report, as well as limitations that are inherent to meta-analyses in general. The specific strains, dosages, and duration of probiotic regimen differed widely. Ideally, the best way to determine the optimal probiotic regimen would be to conduct RCTs comparing specific strains and dosages of probiotics. Given the limited availability of such data, the next-best method is the use of a subgroup analysis. The original article demonstrated the effectiveness of probiotics in reducing the risk of CDAD, and a subgroup analysis identified different efficacies based on probiotic genus. 1 More recently, McFarland reported that there were efficacy differences based on specific species -and that S. boulardii, BioK+ mixture, a mixture of three Lactobacilli strains, and a mixture of L. acidophilus plus B. bifidum are beneficial at reducing the risk of CDAD, while L. rhamnosus GG does not significantly reduce the risk of CDAD.
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